ES2173978T3 - Utilizacion de un alcohol graso insaturado. - Google Patents
Utilizacion de un alcohol graso insaturado.Info
- Publication number
- ES2173978T3 ES2173978T3 ES95936554T ES95936554T ES2173978T3 ES 2173978 T3 ES2173978 T3 ES 2173978T3 ES 95936554 T ES95936554 T ES 95936554T ES 95936554 T ES95936554 T ES 95936554T ES 2173978 T3 ES2173978 T3 ES 2173978T3
- Authority
- ES
- Spain
- Prior art keywords
- provides
- unsaturated fat
- fat alcohol
- pharmaceutical composition
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
ESTA INVENCION PROPORCIONA UNA COMPOSICION TOPICA, EN FORMA DE EMULSION, QUE INCLUYE UN COMPUESTO DE LA CLASE FK506; UN ALCADIOL ACEPTABLE FISIOLOGICAMENTE, DIOL DE ETER O ALCOHOL DE DIETER QUE CONTIENE HASTA 8 ATOMOS DE CARBONO COMO SOLVENTE PARA EL COMPUESTO DE LA CLASE FK506, UN ALCOHOL GRASO INSATURADO Y AGUA. EN OTRO ASPECTO, ESTA INVENCION PROPORCIONA UNA COMPOSICION FARMACEUTICA TOPICA QUE INCLUYE UN MACROLIDO EN SUSPENSION. EN UN ASPECTO AÑADIDO, ESTA INVENCION PROPORCIONA EL USO DE UN ALCOHOL GRASO INSATURADO PARA ESTABILIZAR UN MACROLIDO EN UNA COMPOSICION FARMACEUTICA.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9421612A GB9421612D0 (en) | 1994-10-26 | 1994-10-26 | Organic compounds |
GB9422306A GB9422306D0 (en) | 1994-11-04 | 1994-11-04 | Organic compounds |
GBGB9503553.1A GB9503553D0 (en) | 1995-02-22 | 1995-02-22 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2173978T3 true ES2173978T3 (es) | 2002-11-01 |
Family
ID=27267447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES01117396T Expired - Lifetime ES2243369T3 (es) | 1994-10-26 | 1995-10-26 | Composiciones farmaceuticas. |
ES95936554T Expired - Lifetime ES2173978T3 (es) | 1994-10-26 | 1995-10-26 | Utilizacion de un alcohol graso insaturado. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES01117396T Expired - Lifetime ES2243369T3 (es) | 1994-10-26 | 1995-10-26 | Composiciones farmaceuticas. |
Country Status (26)
Country | Link |
---|---|
US (1) | US6352998B2 (es) |
EP (2) | EP0786986B1 (es) |
JP (3) | JP4155593B2 (es) |
KR (1) | KR100434682B1 (es) |
CN (2) | CN1089233C (es) |
AT (2) | ATE214593T1 (es) |
AU (1) | AU714254B2 (es) |
BR (1) | BR9509530A (es) |
CA (1) | CA2200966C (es) |
CY (1) | CY2211B1 (es) |
CZ (1) | CZ289773B6 (es) |
DE (3) | DE69525957T2 (es) |
DK (2) | DK1147766T3 (es) |
ES (2) | ES2243369T3 (es) |
FI (2) | FI119754B (es) |
GB (1) | GB2308546B (es) |
HK (1) | HK1053611A1 (es) |
HU (1) | HU223840B1 (es) |
MX (1) | MX9702699A (es) |
NO (2) | NO316963B1 (es) |
NZ (2) | NZ295170A (es) |
PL (1) | PL184750B1 (es) |
PT (2) | PT786986E (es) |
SI (1) | SI0786986T1 (es) |
SK (1) | SK284591B6 (es) |
WO (1) | WO1996013249A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
GB9601120D0 (en) * | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
CZ283516B6 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
TW450810B (en) * | 1997-02-20 | 2001-08-21 | Fujisawa Pharmaceutical Co | Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases |
DE19744621A1 (de) * | 1997-10-09 | 1999-04-15 | Muehlbauer Ernst Kg | Mischung zur Verwendung als Wundverband |
GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
DE19802205A1 (de) * | 1998-01-22 | 1999-07-29 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen |
ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
CA2326222C (en) | 1998-04-27 | 2008-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
GB9814640D0 (en) * | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
GB9826656D0 (en) * | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
GB0003932D0 (en) * | 2000-02-18 | 2000-04-12 | Novartis Ag | Pharmaceutical compositions |
WO2002065947A2 (de) * | 2001-02-16 | 2002-08-29 | Abbott Laboratories Vascular Enterprises Limited | Implante mit fk506 zur restenosebehandlung und -prophylaxe |
GB0108498D0 (en) * | 2001-04-04 | 2001-05-23 | Novartis Ag | Organic Compounds |
TWI324925B (en) * | 2001-08-23 | 2010-05-21 | Novartis Ag | Ophthalmic composition |
AR038628A1 (es) * | 2002-03-04 | 2005-01-19 | Novartis Ag | Composicion oftalmica |
GB0218996D0 (en) * | 2002-08-14 | 2002-09-25 | Novartis Ag | Organic compounds |
US20060115522A1 (en) * | 2003-02-17 | 2006-06-01 | Cipla Ltd | Pharmaceutical composition |
GB0307867D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
GB0307866D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
GB0307869D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
AU2004258745A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
RU2375044C2 (ru) * | 2004-04-08 | 2009-12-10 | Новартис Аг | Пимекролимусная пенная композиция, включающая гексиленгликоль, необязательно олеиловый спирт, диметилизосорбид и/или триглицериды со средними цепями |
GB0408070D0 (en) * | 2004-04-08 | 2004-05-12 | Novartis Ag | Pharmaceutical formulations |
GB0508827D0 (en) * | 2005-04-29 | 2005-06-08 | Novartis Ag | Cosmeceutical composition |
WO2008063563A2 (en) | 2006-11-16 | 2008-05-29 | Transderm, Inc. | Methods of treating keratin hyperproliferation disorders using mtor inhibitors |
EP2016935A1 (en) * | 2007-07-09 | 2009-01-21 | Intendis GmbH | Pharmaceutical composition for topical application of poorly soluble compounds |
CN101288643B (zh) * | 2008-06-17 | 2012-11-14 | 杨喜鸿 | 含有他克莫司的凝胶剂组合物及其制备方法和药物应用 |
EP2308468A1 (en) * | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
JP5674786B2 (ja) * | 2010-07-23 | 2015-02-25 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
WO2012011192A1 (ja) * | 2010-07-23 | 2012-01-26 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
CN102552253A (zh) * | 2012-01-17 | 2012-07-11 | 唯美度科技(北京)有限公司 | 一种祛痘用皮肤外用剂 |
WO2013111817A1 (ja) * | 2012-01-25 | 2013-08-01 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
EP2948134B1 (en) * | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
MX367121B (es) * | 2013-08-02 | 2019-08-06 | Laboratorio Raam De Sahuayo S A De C V | Composición sólida estable de inmunosupresores. |
DE102013222164A1 (de) * | 2013-10-31 | 2015-04-30 | Deb Ip Limited | Stabilisierte multiple Emulsionen als Hautschutzprodukt |
US10765665B2 (en) * | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
CN105663027B (zh) * | 2016-04-01 | 2018-12-18 | 中国人民解放军***武汉总医院 | 西罗莫司外用制剂、其制备方法及用途 |
CN109069418A (zh) * | 2016-04-04 | 2018-12-21 | 药品配送方案有限公司 | 包含他克莫司的局部组合物 |
IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
KR101973065B1 (ko) | 2017-09-13 | 2019-04-26 | (주)썬테크 | 풍력 발전기 및 풍력 발전기의 블레이드 팁 |
EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
KR101995905B1 (ko) | 2018-03-27 | 2019-07-04 | (주)썬테크 | 풍력 발전기 및 풍력 발전기의 발전모터 |
WO2019233722A1 (en) * | 2018-06-08 | 2019-12-12 | Almirall, S.A. | Pharmaceutical composition comprising tacrolimus |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4299826A (en) | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
PH26083A (en) | 1987-11-09 | 1992-02-06 | Sandoz Ltd | 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof |
JP2799208B2 (ja) | 1987-12-09 | 1998-09-17 | フアイソンズ・ピーエルシー | マクロ環状化合物 |
KR0159766B1 (ko) * | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
NZ235991A (en) * | 1989-11-09 | 1993-05-26 | Sandoz Ltd | Macrolide compounds and pharmaceutical compositions thereof |
US5061700A (en) | 1989-11-16 | 1991-10-29 | Gordon Jay Dow | Glyceryl acetate ointment vehicles |
JPH05504956A (ja) | 1990-03-12 | 1993-07-29 | 藤沢薬品工業株式会社 | トリシクロ化合物 |
EP0533930A1 (en) | 1990-06-11 | 1993-03-31 | Fujisawa Pharmaceutical Co., Ltd. | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease |
MY110418A (en) | 1990-07-02 | 1998-05-30 | Novartis Ag | Heteroatoms-containing tricyclic compounds. |
ATE150304T1 (de) * | 1990-09-04 | 1997-04-15 | Fujisawa Pharmaceutical Co | Tricyclische verbindungen enthaltende salben |
US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
PH31204A (en) * | 1990-11-02 | 1998-05-05 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
CA2054983A1 (en) | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
US5252732A (en) | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
US5208241A (en) | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5247076A (en) | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
HUT66531A (en) | 1992-05-07 | 1994-12-28 | Sandoz Ag | Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
JPH06183970A (ja) * | 1992-12-16 | 1994-07-05 | Fujisawa Pharmaceut Co Ltd | 医薬用組成物 |
CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
MY110603A (en) | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
DE10199039I2 (de) | 1993-10-22 | 2008-08-07 | Hexal Ag Ind 25 | Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator |
-
1995
- 1995-10-26 PL PL95319599A patent/PL184750B1/pl unknown
- 1995-10-26 DK DK01117396T patent/DK1147766T3/da active
- 1995-10-26 EP EP95936554A patent/EP0786986B1/en not_active Expired - Lifetime
- 1995-10-26 HU HU9701928A patent/HU223840B1/hu active IP Right Revival
- 1995-10-26 BR BR9509530A patent/BR9509530A/pt not_active Application Discontinuation
- 1995-10-26 NZ NZ295170A patent/NZ295170A/xx not_active IP Right Cessation
- 1995-10-26 CZ CZ19971232A patent/CZ289773B6/cs not_active IP Right Cessation
- 1995-10-26 AT AT95936554T patent/ATE214593T1/de active
- 1995-10-26 ES ES01117396T patent/ES2243369T3/es not_active Expired - Lifetime
- 1995-10-26 WO PCT/EP1995/004208 patent/WO1996013249A1/en active IP Right Grant
- 1995-10-26 CA CA002200966A patent/CA2200966C/en not_active Expired - Lifetime
- 1995-10-26 SK SK520-97A patent/SK284591B6/sk not_active IP Right Cessation
- 1995-10-26 MX MX9702699A patent/MX9702699A/es active IP Right Grant
- 1995-10-26 NZ NZ331824A patent/NZ331824A/xx not_active IP Right Cessation
- 1995-10-26 CN CN95195900A patent/CN1089233C/zh not_active Expired - Lifetime
- 1995-10-26 PT PT95936554T patent/PT786986E/pt unknown
- 1995-10-26 DE DE69525957T patent/DE69525957T2/de not_active Expired - Lifetime
- 1995-10-26 SI SI9530589T patent/SI0786986T1/xx unknown
- 1995-10-26 ES ES95936554T patent/ES2173978T3/es not_active Expired - Lifetime
- 1995-10-26 PT PT01117396T patent/PT1147766E/pt unknown
- 1995-10-26 EP EP01117396A patent/EP1147766B1/en not_active Expired - Lifetime
- 1995-10-26 DK DK95936554T patent/DK0786986T3/da active
- 1995-10-26 AT AT01117396T patent/ATE299017T1/de active
- 1995-10-26 DE DE19581804T patent/DE19581804T1/de not_active Ceased
- 1995-10-26 JP JP51431096A patent/JP4155593B2/ja not_active Expired - Lifetime
- 1995-10-26 DE DE69534306T patent/DE69534306T2/de not_active Expired - Lifetime
- 1995-10-26 CN CNB021243700A patent/CN100335063C/zh not_active Expired - Lifetime
- 1995-10-26 KR KR1019970702752A patent/KR100434682B1/ko not_active IP Right Cessation
- 1995-10-26 AU AU38451/95A patent/AU714254B2/en not_active Expired
- 1995-10-26 GB GB9707484A patent/GB2308546B/en not_active Expired - Lifetime
-
1997
- 1997-03-11 FI FI971018A patent/FI119754B/fi not_active IP Right Cessation
- 1997-04-25 NO NO19971951A patent/NO316963B1/no not_active IP Right Cessation
-
2000
- 2000-12-01 CY CY0000067A patent/CY2211B1/xx unknown
-
2001
- 2001-01-23 US US09/767,656 patent/US6352998B2/en not_active Expired - Lifetime
-
2003
- 2003-08-20 HK HK03105954A patent/HK1053611A1/xx not_active IP Right Cessation
-
2004
- 2004-09-08 NO NO2004005C patent/NO2004005I2/no unknown
-
2007
- 2007-02-27 JP JP2007047216A patent/JP2007145860A/ja not_active Withdrawn
- 2007-12-28 FI FI20071025A patent/FI119755B/fi not_active IP Right Cessation
-
2012
- 2012-03-29 JP JP2012077545A patent/JP5599422B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2173978T3 (es) | Utilizacion de un alcohol graso insaturado. | |
MX9202407A (es) | Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion. | |
ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR033808A1 (es) | Una composicion topica de anestesia local y los parches y los envases que la contienen | |
BRPI0509708A (pt) | composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbìdeo e/ou triglicerìdeos de cadeia média | |
PT971705E (pt) | Formulacoes de farmacos de terapeutica de substituicao hormonal para aplicacao topica na pele | |
ES2176795T3 (es) | Composiciones a base de esfingomielanasa y su utilizacion. | |
CO5160321A1 (es) | Novedosas composiciones de tipranavir y ritonavir | |
AR041826A1 (es) | Formulaciones de liberacion prolongada en formas de suspension | |
AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
ES2045768T3 (es) | Composiciones topicas que contienen defibrotida. | |
CO4940430A1 (es) | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales | |
ES2130598T3 (es) | Preparaciones cosmeticas y/o farmaceuticas. | |
SV1998000040A (es) | Composiciones farmaceuticas ref. pu3210/sv | |
ES2120667T3 (es) | Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis. | |
BR9806193A (pt) | Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm | |
MX9307203A (es) | COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS. | |
BR0009194A (pt) | Composição do resorcinol | |
ES2173360T3 (es) | Agentes odoriferos y/o aromaticos. | |
ES2156181T3 (es) | Utilizacion de un disacarido como estabilizante de mezclas liquidas de proteinas y mezclas liquidas de proteinas que contienen un disacarido. | |
ES2175099T3 (es) | Uso de forskolina o extractos que la contienen en la fabricacion de un medicamento para el tratamiento de la adiccion al alcohol. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 786986 Country of ref document: ES |